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Abstract
Bax is the major multidomain proapoptotic molecule that is required for apoptosis. It has been reported that
phosphorylation of Bax at serine(S) 163 or S184 activates or inactivates its proapoptotic function, respectively. To uncover
the mechanism(s) by which phosphorylation regulates the proapoptotic function of Bax, a series of serine (S)R alanine/
glutamate (A/E) Bax mutants, including S163A, S184A, S163E, S184E, S163E/S184A (EA), S163A/S184E (AE), S163A/S184A
(AA) and S163E/S184E (EE), were created to abrogate or mimic, respectively, either single or double-site phosphorylation.
The compound Bax mutants (i.e. EA and AE) can flesh out the functional contribution of individual phosphorylation site(s).
WT and each of these Bax mutants were overexpressed in Bax
2/2 MEF or lung cancer H157 cells and the proapoptotic
activities were compared. Intriguingly, expression of any of Bax mutants containing the mutation SRA at S184 (i.e. S184A,
EA or AA) represents more potent proapoptotic activity as compared to WT Bax in association with increased 6A7 epitope
conformational change, mitochondrial localization/insertion and prolonged half-life. In contrast, all Bax mutants containing
the mutation SRE at S184 (i.e. S184E, AE or EE) have a mobility-shift and fail to insert into mitochondrial membranes with
decreased protein stability and less apoptotic activity. Unexpectedly, mutation either SRAo rS RE at S163 site does not
significantly affect the proapoptotic activity of Bax. These findings indicate that S184 but not S163 is the major
phosphorylation site for functional regulation of Bax’s activity. Therefore, manipulation of the phosphorylation status of Bax
at S184 may represent a novel strategy for cancer treatment.
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Introduction
Programmed cell death/apoptosis plays a critical role in normal
development and maintenance of tissue homeostasis. This impor-
tant cellular apoptotic process eliminating unwanted or damaged
cells that prevents cancer development is mainly activated through
intrinsic and extrinsic apoptotic pathways [1–2]. The extrinsic
pathway is mediated by cell surface death receptor, such as TNF
alpha receptor 1 (TNFR1), CD95/Fas and TRAIL, which activates
caspase-8 followed by caspase-3 activation, while intrinsic pathway
is characterized by mitochondrial dysfunction and activation of
caspase 9 and Apaf-1 by cytochrome c (Cyt c) and other proteins
including apoptosis inducing factor (AIF), Smac/Diablo and Endo
G [1,3,4]. Bcl2 family members play a vital role in intrinsic
apoptotic pathway by controlling outer mitochondrial membrane
permeabilization (OMMP) [3,5]. While the anti-apoptotic proteins,
such as Bcl2, Bcl-XL and Mcl-1, prevent the release of Cyt c and
AIF from mitochondria, the pro-apoptotic proteins, which are
divided into two groups, including the multidomain-BH1-3 proteins
(i.e. Bax and Bak) and the BH3-only proteins (i.e. Bid, Bim, Bik, Bid
and Puma), facilitate apoptosis. Bax and Bak have been shown to be
required for the intrinsic apoptotic pathway [6]. Bax is normally
distributed in cytoplasm or loosely associated with mitochondrial
membrane, whereas Bak is tightly associated with mitochondrial
membrane [7–9]. Upon stimulation of apoptosis, Bax can be
induced to undergo conformational change followed by formation
of membrane-inserted homo-oligomers that result in OMMP
[5,10]. The anti-apoptotic proteins, such as Bcl2 and Bcl-XL,
inhibit Bax conformational change and insertion into outer
mitochondrial membrane, whereas BH3-only proteins activate
Bax by binding to and antagonizing anti-apoptotic proteins or
directly binding to and activating Bax [11–14]. Besides anti-
apoptotic proteins of Bcl2 family and BH3-only proteins of this
family, several non-Bcl2-related proteins, including Bif-1 [15–16],
14-3-3[17], humanin (HN) peptide [18] and p53[19–21], have also
been reported to be involved in regulation of Bax activity. Bif-1
binds to and activates Bax, and p53 was shown to translocate from
nucleus to mitochondria to induce Bax activation and Cyt c release
[19], whereas14-3-3 and HN peptide inhibit Bax activity via direct
interaction with this pro-apoptotic protein in cells [17–18].
Phosphorylation has been demonstrated to functionally regulate
most of Bcl2 family members. For instance, phosphorylation of
Bcl2 has been reported to enhance its anti-apoptotic capability
[22], whereas serine (S) phosphorylation of the pro-apoptotic
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reported that activation of AKT blocks conformational change of
Bax as well as its translocation to mitochondria under stress stimuli
[24]. The residue S184 in the C-terminus of Bax is a major site
that can be phosphorylated in neutrophils in an AKT-dependent
manner and phosphorylation at S184 is essential for the cytosolic
retention of Bax [25]. In support of these findings, we recently
discovered that nicotine can stimulate Bax phosphorylation at
S184 through activation of AKT in association with increased
survival and chemoresistance of human lung cancer cells [26].
Inversely, PP2A-mediated dephosphorylation of Bax at S184
enhances the proapoptotic function of Bax [27]. Another
phosphorylation site of Bax is S163 that has been shown to be
phosphorylated by GSK-3b in vitro and in vivo, which is associated
with promotion of apoptosis in neuronal cells [28]. Moreover, it
has recently been demonstrated that Bax can also be phosphor-
ylated at threonine(T)167 site by stress-activated JNK and/or p38
kinase, which leads to Bax activation and mitochondrial
localization prior to apoptosis [29].
The proapoptotic activity of Bax can be regulated by
phosphorylation but the molecular mechanism(s) involved is not
fully understood. The purpose of this study is to investigate the
mechanism of how phosphorylation status of Bax at distinct site(s)
affects the Bax-mediated mitochondrial cell death pathway. Here
we chose the site-directed mutagenesis approach to generate the
non-phosphorylatable and the phosphomimetic Bax mutants at
different site(s). Results indicate that the S184 phosphorylation site
plays a more important role than the S163 phosphorylation site in
regulating the proapoptotic function of Bax.
Materials and Methods
Materials
Bax, Cyt c, prohibitin and caspase 3 antibodies were obtained
from Santa Cruz Biotechnology (Santa Cruz, CA). T7 tag antibody
was purchased from Novagen (San Diego, CA). Dual luciferase
assay kit was purchased from Promega (Madison, WI). MitoTracker
Red CM-H2XRos was purchased from Invitrogen-Molecular
Probes (Carlsbad, CA). 6A7 antibody was obtained from BD
PharMingen (San Diego, CA). Cyclohexamide was purchased from
Sigma (St. Louis, MO). The site-directed mutagenesis kit was
obtained from Clontech (Palo Alto, CA). Mitochondrial membrane
potential detection kit was obtained from Cell Technology, Inc.
(Mountain View, CA). All other reagents used were obtained from
commercial sources unless otherwise stated.
Plasmids, cDNA, cell lines and transfections
A series of the nonphosphorylatable and phosphomimetic at
single site (i.e. S163 or S184) or the compound Bax mutants,
including S163A, S184A, S163E, S184E, S163E/S184A (EA),
S163A/S184E (AE), S163A/S184A (AA) and S163E/S184E (EE),
were created as described previously [22]. The 59 phosphorylated
mutagenic primers for mutating S163 or S184 were synthesized as
follow: S163A, 59GAA GGC CTC CTC GCC TAC TTC GGG
ACC 39; S163E, 59 GAA GGC CTC CTC GAG TAC TTC
GGG ACC 39; S184A, GTC CTC ACC GCC GCG CTC ACC
ATC TGG 39; S184E, GTC CTC ACC GCC GAG CTC ACC
ATC TGG 39. The T7-tagged WT-Bax/pUC19 construct was
used as the target plasmid which contains a unique NdeI
restriction site for selection against the unmutated plasmid. The
NdeI selection primer is: 59 GAG TGC ACC ATG GGC GGT
GTG AAA 39. Nucleotides corresponding to each serine (S)
residue were substituted to create a conservative alteration to
alanine (A) or glutamic acid (E) with a site-directed mutagenesis kit
(Clontech) according to the manufacturer’s instructions. Based on
individual site Bax mutant(s), the compound Bax mutants were
further created using a similar approach. Each single mutant was
confirmed by sequencing of the cDNA and was then cloned into
the pCIneo (Promega) mammalian expression vector. The pCIneo
plasmid containing each Bax mutant cDNA was transfected into
Bax
2/2 MEF cells (a kind gift from Dr. Douglas R. Green, St Jude
Childrens Research Hospital, Memphis, Tennessee 38105, USA)
or human lung cancer H157 cells (obtained from ATCC,
Manassas, VA) using Lipofectamine
TM 2000 (Invitrogen). The
expression levels of exogenous Bax were compared by Western
blot analysis using a Bax antibody.
Fluorescent immunostaining
For examining the Bax subcellular localization, Bax
2/2MEF
cells were grown on a 2-well Lab-Tek chamber slide (Nalge Nunc,
Naperville, IL) and transfected using 2 mg of plasmid DNA and
5 ml of Lipofectamine 2000. After 16–18 h of incubation, the
transfected cells were incubated with 20 ng/ml of a mitochondri-
on-specific dye (Mitotracker red CMXRos; Molecular Probes Inc.,
Eugene, OR) for 30 minutes, then fixed and permeablized with
methanol and acetone (1:1) for 5 minutes, and then blocked with
10% normal goat serum for 20 minutes at room temperature. A
T7 mouse monoclonal antibody with dilution of 1:2000 was added
to incubate with cells at RT for 90 minutes. After washing, cells
were incubated with Alexa Fluor 488 conjugated goat anti-mouse
secondary antibody for 40 minutes. Cells were washed with 1x
PBS at least four times and observed under a fluorescent
microscope (Zeiss). Pictures were taken and colored with the
same exposure setting for each experiment.
Subcellular fractionation
Cells (2610
7) were washed with cold 16PBS and resuspended in
isotonic mitochondrial buffer (210 mM mannitol, 70 mM sucrose,
1 mM EGTA, 10 mM Hepes, pH 7.5) containing protease
inhibitor mixture set I (Calbiochem), homogenized with a Polytron
homogenizer operating for four bursts of 10 s each at a setting of 5,
and then centrifuged at 20006g for 3 min to pellet the nuclei and
unbroken cells. The supernatant was centrifuged at 13,0006g for
10 min to pellet mitochondria as described previously [26]. The
second supernatant was further centrifuged at 150,0006g to pellet
light membranes. The resulting supernatant is the cytosolic fraction.
Mitochondria were washed with mitochondrial buffer twice,
resuspended in 1% Nonidet P-40 lysis buffer, rocked for 60 min,
and then centrifuged at 17,5306g for 10 min at 4uC. The resulting
supernatant containing mitochondrial proteins was collected.
Protein (100 mg) from each fraction was subjected to SDS-PAGE.
The purity of each fraction was confirmed by assessing localization
of the mitochondria-specific protein prohibitin [30].
Immunoprecipitation
To test Bax conformational change, Bax
2/2 MEF cells
expressing WT and each of various Bax mutants were lysed using
lysis buffer containing CHAPS (150 mM NaCl, 10 mM Hepes
pH 7.5, 1% CHAPS). The cell lysate was incubated with 2 mgo f
6A7 antibody (BD Pharmingen, San Diego, CA) and 20 ml protein
G agarose beads overnight at 4uC. After washing, the resulting
beads were boiled with SDS loading sample buffer and subjected
to SDS-PAGE for Western blot analysis.
Alkali extraction to detect Bax insertion
Bax
2/2 MEF cells were transfected using pCIneo empty vector,
WT and each of Bax mutants. The isolated mitochondria were
Phosphorylation Regulates Bax
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incubated on ice for 30 min. The samples were then centrifuged at
200,0006g for 30 min, and the alkali-resistant pellet was resus-
pended with 1% Nonidet P-40 lysis buffer, rocked for 60 min, and
then centrifuged at 17,5306g for 10 min at 4uC. The supernatant
containing the nonextractable mitochondrial proteins was collected
and subjected to SDS-PAGE. The alkali-resistant Bax (i.e.
nonextractable or integral) was determined by Western blot using
a Bax antibody as described previously [31–32].
Measurement of Cyt c release
To assess cytochrome C release, mitochrondrial and cytosolic
fraction were obtained by use of a digitonin-based subcellular
fractionation as described [33–34]. Equal amount protein of
mitochrondial and cytosolic fractions was subjected to SDS-PAGE
followed by immunoblotting with anti-Cyt c antibody.
Measurement of the Bax half-life
Cycloheximide half-life assay was performed as described [35].
Briefly, WT and each of Bax mutants were transfected into Bax
2/2
MEF cells. After 18 h, cyclohexamide (100 mg/ml) was added
5 min prior to starting the indicated time course to block new
protein synthesis. Cells were collected and lysed at the indicated
times. Bax in total cell lysate was analyzed by Western blot using
Baxantibody.TomoreaccuratelyquantifytheturnoverrateofBax,
a classical
35S-methionine pulse–chase method was also employed.
Cells expressing WT and each of Bax mutants were metabolically
labeled with
35S-methionine for 60 min. The
35S-methionine-
labeled cells werewashed and incubated in fresh methionine-replete
RPMI medium 1640 for various time points up to 12 h.
35S-labeled
Bax was immunoprecipitated by using Bax antibody. The samples
were subjected to SDS/10–20% PAGE. The half-life (t1/2) of Bax
was determinedby electronicautoradiography as described [22,36].
Cell viability assay
After transfection of WT or each of Bax mutants into Bax
2/2
MEF or H157 cells using LipofectAMINE
TM 2000 (Invitrogen),
apoptotic and viable cells were detected using an ApoAlert
Annexin-V kit (Clontech) according to the manufacturer’s instruc-
tions. The percentage of annexin-V
low (i.e. viable) or annexin-V
high
(i.e. apoptotic) cells was determined using the data obtained by
fluorescence-activated cell sorter analysis as described [36–37].
Additionally, cell viability was also analyzed by luciferase assay as
described [38–39]. The mammalian expression vector pGL3
(Promega) carrying the firefly luciferase (Luc) gene was co-
transfected with WT or each of Bax mutants. A molar ratio of 1:4
(pGL3: Bax plasmid) was used to co-transfect in Bax
2/2 MEF or
H157 cells in 6-well tissue culture plates. After 48 h, cells were
harvested and processed using the luciferase assay system
(Promega). Luciferase activity was measured by liquid scintillation
counting (Monolight 3010, PharMingen) using 20 ml of the cellular
extract. In every experiment, each construct was tested in triplicate,
and experiments were repeated three times. Cell viability is shown
as the relative luciferase activity of the tested plasmids compared to
the vector-only control as described [38–39].
Measurement of mitochondrial membrane potential
Mitochondrial membrane potential (DY) was measured using
an DY assay kit (Cell Technology, INC) according to the
manufacturer’s instruction. Briefly, Bax
2/2 MEF cells in 6-well
plates were transiently transfected with empty pCIneo vector, WT
or each of Bax mutants for 16 hours. 10 ml of 30X mitochondrial
membrane potential dye was added to each well. After incubation
for 30 min, cells were trypsinized, washed with 16 wash buffer
and analyzed by flow cytometry.
Results
The effects of mono- and double-site phosphorylation of
Bax on its proapoptotic function
To directly test and compare the function and potency of mono-
and double-site phosphorylation, a series of SRAo rS RE Bax
mutants were created to abrogate or mimic, respectively, the
charge conferred by phosphorylation (Fig. 1A). After transfection
of these Bax mutants into Bax
2/2 MEF cells, the Western blot
analysis indicates that introduction of E at the S184 site produces a
shifted mobility of Bax band following denaturing electrophoresis.
Since only individual S184E, AE and EE but not S163E or EA
Bax mutants show this mobility pattern (Fig. 1A), suggesting that
the charge conferred by phosphorylation at S184 but not S163 site
is essential for inducing this specific conformational change
responsible for Bax’s altered mobility. We further examined the
proapoptotic activities of WT and each of various Bax mutants
using an ApoAlert Annexin-V kit as described [36–37]. Interest-
ingly, the mutant S184A has more apoptotic activity than WT
Bax, and S184E mutant Bax has no significant apoptotic effect on
cells. The mutant S163A has no significant difference in apoptotic
activity as compared to S163E or WT Bax. The mutants S184E,
AE and EE lost their death activities because viabilities of cells
expressing these mutants are close to vector-only control. The
mutant EA and AA had similar levels of proapoptotic activity as
S184A Bax mutant. The ordering of proapoptotic activity for
the mutants as follow: S184A<EA<AA.WT<S163A <S163E.
S184E<AE<EE (Fig. 1B). Our findings suggest that the S184
perhaps not the S163 is a critical phosphorylation site in regulating
Figure 1. Mono-or double-site Bax phosphorylation regulates
its proapoptotic activity. A, The pCIneo empty vector, T7-tagged WT
and each of A- or E-Bax mutant cDNAs were transfected in Bax
2/2 MEF
cells. After 24 h, expression levels of exogenous Bax protein were
determined by Western blot using T7 antibody. B, After transfection
with WT or each of Bax mutants for 48 h, cell viability was determined
by analyzing annexin-V binding on FACS. Data represent the mean 6
S.D. of three determinations.
doi:10.1371/journal.pone.0013393.g001
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causes a conformational change (i.e. mobility shift) which may
inactivate Bax’s proapoptotic function. To rule out a possible cell
type or species-specific effect for E- or A-Bax mutants, similar
studies were performed in human H157 epithelial lung cancer
cells using luciferase assay for evaluating cell viability as described
[38–39]. This assay is based on the reduction in expression of a
luciferase reporter gene that was co-expressed with WT or each of
Bax mutants. Overexpression of the proapoptotic Bax is supposed
to reduce the luciferase activity in cells. Consistently, similar results
were obtained in H157 cells (Fig. S1). This confirms a functional
role for Bax phosphorylation in regulating apoptosis that is not
limited to a specific cell type or species.
Phosphorylation of Bax at S163 and S184 distinctly
regulates its subcellular localization
Bax translocation from cytosol to mitochondria is an essential
event for Bax-mediated intrinsic apoptosis pathway. Cytosolic Bax
protein becomes mitochondria-bound in cells undergoing apop-
tosis [1]. It was reported that C-terminus of Bax plays a critical
role in regulation of Bax subcellular localization, deletion of 10 or
even only five amino acids from the hydrophobic tail that consists
of a total of 21-amino acids could prevent Bax mitochondrial
membrane insertion and abrogate its proapoptotic activity [2].
To uncover the mechanism(s) by which Bax phosphorylation
regulates its proapoptotic function, subcellular distribution of WT
and each of Bax mutants were examined by immunofluorescent
staining and subcellular fractionation analyses. After transient
transfection of WT and each of Bax mutants in Bax
2/2 MEF cells,
mitotracker and immunofluorescent double stainings indicate that
S184A, EA and AA Bax mutants are more co-localized with
mitotracker red CMXRos since their emerged images represent
stronger yellow color (Fig. 2A). Additionally, S184A and AA Bax
mutants represent punctuate, mitochondrial localization. In contrast,
S184E and EE Bax mutants have diffuse, cytoplasmic localization
(Fig. 2A). WT and other Bax mutants have mixed localizations (i.e.
diffusepluspunctuate).Consistently, subcellular fractionation analysis
reveals that WT, S163A and S163E are localized in both cytosol and
mitochondria. S184A, EA and AA Bax mutant proteins are
completely localized in mitochondrial membranes while S184E, AE
and EE are totally localized in cytosol (Fig. 2B), which support the
findings from immunofluorescent staining. To confirm the purity of
the subcellular fractions obtained, fraction-specific proteins were
assessed by probing the same filters. Prohibitin, an exclusively
mitochondrial protein [30], was detected only in the mitochondrial
fraction whereas caspase 3, which is a cytosolic protease in growing
cells [40], was detected exclusively in the cytosol (Fig. 2B). These
resultsindicatethatthemitochondrialand cytosolicfractionsarepure
without the artifactual cross-contamination.
Effect of Bax phosphorylation on its 6A7 epitope
conformational change
To determine whether the phosphorylation status of Bax affects
its active conformational change, an anti-6A7 Bax antibody that
specifically measures the conformational change of Bax was used.
The monoclonal antibody 6A7, raised against the peptide amino
acids 13–19 in the N terminus of Bax, is not able to bind the soluble
form of Bax in healthy cells but can recognize Bax after the
conformational change associated with membrane insertion occurs
in apoptotic cells [41–42]. Recent studies further demonstrated that
the 6A7 Bax antibody only recognizes conformationally changed,
active Bax [27]. Immunoprecipitation experiment using 6A7
antibody reveals that S184A, EA and AA mutants have more
abilities to bind to 6A7 antibody as compared to WT, S163A and
S163E Bax mutants. Intriguingly, S184E, AE and EE lack abilities
to bind to 6A7 antibody (Fig. 3). These findings suggest that the
S184 nonphosphorylatable Bax or dephosphorylation of Bax at
S184 site may cause a conformational change by exposure of 6A7
epitope that leads to activation of the proapoptotic function of Bax,
which is functionally opposite with the mobility shift derived from
thephosphomimeticmutationatthissite(i.e.S184E;Fig.1vs.Fig.3).
Phosphorylation of Bax regulates its ability to insert into
mitochondrial membrane and induce cytochrome c
release
In health cells, Bax is primarily located at the cytosol where it
may be loosely associated with the outer mitochondrial mem-
brane. Upon induction of apoptosis, Bax is translocated to
mitochondria and becomes integrally associated with the outer
mitochondrial membrane [3]. It has been demonstrated that an
alkali extraction approach can distinguish whether Bax protein
associates with or inserts into mitochondrial membranes [31]. An
alkali extraction experiment was employed to test whether Bax
phosphorylation at different sites regulates its capacity to insert
into mitochondrial membranes. Mitochondria were isolated from
Bax
2/2 MEF cells that express exogenous WT and each of Bax
mutants and incubated in 0.1 M Na2CO3 (pH 11.5) on ice for
30 min and centrifuged at 200,0006g to yield a mitochondrial
pellet. The resulting alkali extracted mitochondrial membrane
pellet will be resuspended in 1% NP-40 lysis buffer. The alkali-
resistant, integral Bax will be analyzed by Western blot. Results
reveal that S184A, EA and AA mutants display more Bax proteins
resistant to alkali extraction as compared to WT, S163A and
S163E mutants (Fig. 4A). In contrast, S184E, AE and EE mutant
proteins could not be observed in mitochondrial membranes after
alkali treatment (Fig. 4A). These findings reveal that S184A, EA
and AA mutant Bax proteins have more ability to insert into
mitochondrial membranes and that S184E, AE and EE mutant
proteins lost this capacity. To further test whether the mitochon-
drially inserted Bax promotes Cyt c release, subcellular fraction-
ation experiments were carried out in cells expressing WT or each
of A- or E-Bax mutants. Consistently, S184A, EA and AA Bax
mutants more potently induce Cyt c release as compared to WT,
S163A and S163E mutants (Fig. 4B). In contrast, S184E, AE and
EE lost their abilities to induce Cyt c release (Fig. 4B).
Phosphorylation of Bax reduces its stability
It has been demonstrated that Bax degradation occurs through the
ubiquitin/proteasome-dependent pathway and inhibition of Bax
degradation enhances the proapoptotic function of Bax [43]. To test
how Bax phosphorylation at S163 and S184 affects its stability, a
cycloheximide half-life (t1/2) assay was performed in cells expressing
WT or A- or E-containing Bax mutants as described [35]. To more
accurately evaluate the turnover rate of WT or A- or E-containing
Bax mutants, we also used the classical
35S-methionine pulse–chase
method to quantify the half-life (t1/2)o fB a xb ye l e c t r o n i c
autoradiography as we previously described [22,36]. The t1/2 of
S184E, AE and EE was found to be significantly shorter
(i.e.3.5,4.3 h) than that of WT Bax (i.e. 11.5 h). In contrast,
S184A, EA and AA have a significant longer half-life (i.e.
14.2,19.1 h). The t1/2 of S163A or S163E is shorter than WT but
longer than S184E (Fig. 5). These results indicate that the charge
conferred by phosphorylation at S184 significantly reduces Bax’s
stability to turnover. Therefore, we propose that placing a charge
equivalent to a phosphate at the S184 phosphorylation site in the C-
terminus will, in addition to directly inactivating Bax’s proapoptotic
Phosphorylation Regulates Bax
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survival (Figs 1 and 5). The nonphosphorylatable S184A containing
Bax mutants have enhanced stability to proteolysis, which may
further enhance the proapoptotic function of Bax.
Effect of Bax phosphorylation on mitochondrial
membrane potential (DY)
The mitochondrial permeability transition is an important step
in the induction of cellular apoptosis. During this process, the
electrochemical gradient across the mitochondrial membrane
collapses. This collapse may occur through the formation of pores
in the mitochondria by activated, dimerized Bax [44]. After
transfection of WT or each of Bax mutants, DY was analyzed as
described [45]. The cationic dye is cell permeable and has strong
fluoresecent signal and exhibits low membrane potential indepen-
dent binding and toxicity. In healthy cells, cationic dye is
accumulated by the mitochondria in proportion to membrane
potential. In apoptotic cells, where DY is compromised, the
Figure 2. Effect of Bax phosphorylation on its subcellular distribution. A, After transfection of WT or each of Bax mutants in Bax
2/2 MEF
cells, cells were incubated with Mitotracker CMXRos (red). After fixation, cells were stained with T7 antibody and Alex 488 conjugated secondary
antibody and observed under a fluorescent microscope. B, Subcellular fractionation was performed to isolate mitochondrial and cytosolic fractions
from Bax
2/2 MEF cells expressing exogenous WT or each of Bax mutants. Bax protein was analyzed by Western blot using a T7 antibody. The purity
for each fraction was monitored by analyzing the fraction-specific proteins (i.e. prohibitin, a mitochondrial marker; caspase 3, a specific cytosolic
protein).
doi:10.1371/journal.pone.0013393.g002
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cells exhibit a lower fluorescence signal. Consistently, expression of
S184A, EA or AA mutant Bax causes more DY loss as compared
to WT, S163A and S163E mutants. In contrast, expression of
S184E, AE or EE mutant Bax did not significantly lose DY (Fig. 6).
Discussion
The Bcl2 family lies at the central of the intrinsic pathway to
apoptosis, the interactions between the family members being
critical fordeterminingthe fateofacell(i.e.aliveor dead)[46–47].
The multi-domain pro-apoptotic members, including Bax and
Bak, have been demonstrated that one or other of these proteins
are required for apoptotic cell death through the release of
apoptogens from mitochondria [6,48]. However, the mechanism
by which the cell death mediator Bax becomes activated to cause
mitochondrial damage remains elusive. Mounting evidence
indicates that the proapoptotic function of Bax can be regulated
by phosphorylation at various sites through activation of various
protein kinases, including PI3K/AKT [25–26], GSK-3b [28],
JNK and p38 kinases [49]. Intriguingly, phosphorylation at S163
and S184 has been reported to play an inverse role in regulating
the proapoptotic function of Bax [25–26,28]. To flesh out the
functional contribution of individual phosphorylation site(s), we
chose to abrogate Bax phosphorylation by introducing a
conserved, non-phosphorylated alanine (A) at the S163 or S184
phosphorylation site(s). Similar mutant(s) carrying a glutamate (E)
at these same sites were prepared in order to functionally mimic
the charge conferred by the phosphate (i.e. phosphomimetic). The
power of this genetic approach is intensified in these studies
because a direct comparison can be made between the non-
phosphorylatable (i.e.S RA) and phosphomimetic (i.e.S RE) Bax
mutants expressed at the same levels in the same cell types. We
believe that this comparative approach can provide a definitive
answer to explain how, and at which site(s) phosphorylation
affects the proapoptotic function of Bax.
Results clearly indicate that the non-phosphorylatable S184A-
containing Bax mutants (i.e. S184A, EA and AA) function as
active forms of Bax, which exhibit the highest cell killing activity.
Inversely, the phosphomimetic S184E-containing mutants (i.e.
S184E, AE and EE) almost lost their proapoptotic activities
(Figs. 1 and S1). These findings support and extend our and
others’ previous studies that phosphorylation of Bax at S184 can
inactivate the proapoptotic function of Bax and that dephos-
phorylation of Bax at this site renders Bax more potent killing
capacity [25–27]. However, levels of the killing activity of the
non-phosphorylatable S163A and the phosphomimetic S163E
have no significant difference as compared to WT Bax (Fig. 1).
This suggests that phosphorylation or dephosphorylation of Bax
at S163 site may not significantly alter its proapoptotic function.
These results are difficult to reconcile with previous report that
GSK-3b-induced Bax phosphorylation at S163 activates its
proapoptotic function in neuronal cells [28]. While the reason for
Figure 3. Effect of Bax phosphorylation on its 6A7 epitope
conformational change. Immunoprecipitation was performed using
6A7 antibody in total lysates isolated from Bax
2/2 MEF cells expressing
exogenous WT or each of Bax mutants. The 6A7 epitope conformation-
ally changed Bax was analyzed by Western blot using a Bax antibody.
doi:10.1371/journal.pone.0013393.g003
Figure 4. Role of Bax phosphorylation in regulating its abilities to insert mitochondrial membranes and induce Cyt c release. A,
Mitochondria were isolated from Bax
2/2 MEF cells expressing exogenous T7-tagged WT or each of Bax mutants and alkali extraction of Bax was
performed as described under ‘‘Experimental Procedures.’’ The alkali-resistant Bax (i.e. nonextractable) was determined by Western blot using a T7
antibody. Prohibitin, an inner mitochondrial membrane protein, was used as control. B, Subcellular fractionation was performed to isolate
mitochondria and cytosol. The release of Cyt c from mitochondria into cytosol was detected by Western Blot using Cyt c antibody.
doi:10.1371/journal.pone.0013393.g004
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from a cell-type specific effect. Since results reported here are
obtained by direct comparison of the Bax mutants that either
carry charge that mimics phosphorylation or a mutation unable
to accept a phosphate charge, we propose that S184 but not S163
is the major Bax phosphorylation site that can regulate the
proapoptotic function of Bax by manipulating the phosphoryla-
tion status at this site.
A conformational change conferred by exposure of 6A7
epitope in the N-terminus (amino acids 13–19) has been
demonstrated to activate the proapoptotic function of Bax
[27,41–42]. Here our findings reveal that destruction of the
S184 phosphorylation site by alanine substitution (i.e.S RA) can
cause such a conformational change (i.e. exposure of 6A7 epitope)
because the S184A containing Bax mutants (i.e. S184A, EA and
AA) have more abilities to bind to 6A7 antibody (Fig. 3).
Importantly, these Bax mutants with the 6A7 epitope confor-
mational change function as active forms of Bax that more
efficiently insert into mitochondrial membranes leading to Cyt c
release and apoptosis (Figs 1 and 4). Interestingly, mimicking
phosphorylation at S184 site by a glutamate substitution (i.e.
SRE) in the C-terminal tail of Bax results in another type of
conformational change that represents a mobility-shift (Fig. 1A)
but the functional significance of this conformational change
remains unclear. Because the S184E-containing Bax mutants (i.e.
S184E, AE and EE) with mobility-shift lost their abilities to target
and insert into mitochondrial membranes, which eventually fails
to induce Cyt c release from mitochondria (Figs 2 and 4).
Additionally, this conformational change with mobility-shift
renders Bax more sensitive to degradation (Fig. 5). Based on
these important findings, we propose that the conformational
change conferred by S184 site phosphorylation may directly
inactivate the proapoptotic function of Bax. Since the confor-
mational change(s) and the proapoptotic activity of Bax are
dependent on the S184 but not the S163 phosphorylation site,
manipulation of the phosphorylation status at S184 should
represent novel strategies for treatment of cancer by altering the
apoptotic activity of Bax in tumor cells.
Supporting Information
Figure S1 Mono-or double-site Bax phosphorylation regulates
its proapoptotic activity in H157 cells.
Found at: doi:10.1371/journal.pone.0013393.s001 (0.09 MB
PDF)
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Figure 5. Effect of Bax phosphorylation status on its half-life in
cells. A, Bax
2/2 MEF cells expressing exogenous WT or each of Bax
mutants were treated with 100 mg/ml cycloheximide 5 min prior to
starting the indicated time course. Bax was analyzed by Western blot. B,
Bax
2/2 MEF cells expressing exogenous WT or each of Bax mutants
were metabolically labeled with
35S-methionine. The half-life of Bax was
determined by classic pulse-chase analysis. Data represent the mean 6
S.D. of three determinations.
doi:10.1371/journal.pone.0013393.g005
Figure 6. Effect of Bax phosphorylation on mitochondrial
membrane potential. The pCIneo empty vector, WT or each of Bax
mutants were transfected into Bax
2/2 MEF cells. After 16 h, cells were
stained with cationic dye and analyzed by FACS. Data represent the
mean 6 S.D. of three determinations.
doi:10.1371/journal.pone.0013393.g006
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